Researchers Submit Patent Application, "Immunomodulatory Clinical Biomarker Profiles And Uses Thereof", for Approval (USPTO 20240027460).

Researchers from Seattle Children's Hospital have developed a method for selecting a therapeutic agent for immunomodulatory treatment based on biomarker profiles. These profiles can differentiate between patients who will have a positive response to treatment with limited or no neurotoxicity and those who will have a toxic response or no response at all. The method involves measuring specific biomarkers or biomarker cell populations in a biological sample and comparing them to a reference profile to determine the likelihood of a functional response. This method could help predict and prevent adverse events in patients undergoing immunotherapy and guide treatment decisions. The patent application also discusses potential therapeutic agents that can be used alongside immunomodulatory treatments to promote a positive response. [Extracted from the article]